The impact of the COVID-19 pandemic on liver health: exploring shifts in social and psychosocial determinants of steatosis and fibrosis

Yuan Zhao, Xuanhui Li, Jiacheng Cheng, Dongyu Hu, Huili Cao, X. Wang, Junhua He, Yikun Zhu, Jin LiFrontiers in Medicine 2026 · DOI

Abstract

The pandemic period was associated with substantial changes in the epidemiology and psychosocial-behavioral correlates of steatotic liver disease (SLD) and fibrosis, with notable sex-specific differences.

Introduction

Steatotic liver disease (SLD) represents a significant global health burden, traditionally understood through metabolic and behavioral lenses. However, the progression of liver fat (steatosis) to scarring (fibrosis) is deeply intertwined with social and psychosocial determinants of health. The COVID-19 pandemic served as a global disruptor, altering dietary habits, physical activity levels, and mental health. This study investigates how these disruptions fundamentally rewired the risk profiles for metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-associated liver disease (ALD), and the hybrid MetALD.

Methodology

This research utilized a repeated cross-sectional design based on data from the National Health and Nutrition Examination Survey (NHANES). The study population comprised 6,090 adults, divided into a pre-pandemic cohort (2017–March 2020, n=3,621) and a pandemic-period cohort (2021–2023, n=2,469).

Liver health was assessed using Vibration-Controlled Transient Elastography (VCTE) to obtain the Controlled Attenuation Parameter (CAP) for steatosis and Liver Stiffness Measurement (LSM) for fibrosis. To address the low prevalence of conditions like ALD and MetALD in general surveys, the researchers employed Firth’s penalized-likelihood logistic regression. Interaction modeling via Ratios of Odds Ratios (RORs) was used to quantify shifts in the strength of associations between social determinants and liver disease across the two periods.

Results

The study revealed a paradoxical shift in liver disease epidemiology. While age-standardized MASLD prevalence declined from 32.2% to 28.6% (primarily in men), the rate of advanced fibrosis (F3) nearly doubled from 2.6% to 4.2%, with a particularly sharp increase observed in women (2.0% to 3.6%).

Table 1 (Part 2): Behavioral and clinical characteristics of the study population across pre-pandemic and pandemic periods.

Psychosocial factors emerged as critical drivers during the pandemic. In men, the association between depressive symptoms and ALD risk intensified significantly (OR = 5.31). Similarly, smoking became a much more potent risk factor for ALD, with the Odds Ratio rising from 3.49 pre-pandemic to 17.08 during the pandemic period.

Table 1 (Part 3): Clinical markers and dietary composition shifts between the pre-pandemic and pandemic cohorts.

Clinical and dietary data suggested a bifurcation in the population. While general metabolic markers showed modest improvements—potentially linked to slight reductions in energy and carbohydrate intake—the most vulnerable individuals experienced rapid progression toward severe liver damage.

Discussion

The pandemic appears to have eroded traditional "protective" buffers. Before 2020, higher income and regular physical activity were strongly associated with lower liver disease risk. Post-pandemic, physical activity lost its protective significance, likely due to structural changes in how and where people exercised. Furthermore, financial stability (high income) no longer provided a significant buffer against MetALD (ROR = 0.21), suggesting that the era's unique stressors transcended socioeconomic status.

Sex-specific vulnerabilities were also prominent. Women were more susceptible to advanced fibrosis and MetALD when facing unemployment. Conversely, an interesting protective factor emerged for women during the pandemic: longer weekend sleep (≥8 hours) was significantly associated with reduced fibrosis risk.

Conclusion

The COVID-19 pandemic did not merely change the prevalence of liver disease; it altered the "rules" of vulnerability. The emergence of depression as a primary biological driver and the loss of traditional protective factors necessitate a shift in clinical approach. Future prevention and treatment strategies for SLD must integrate mental health support and address social determinants rather than focusing exclusively on metabolic management. Longitudinal research is required to determine if these shifts represent a permanent "new normal" in hepatology.

Summary updated

Abstract

The pandemic period was associated with substantial changes in the epidemiology and psychosocial-behavioral correlates of SLD and fibrosis, with notable sex-specific differences.
BibTeX
@inproceedings{zhao2026impact,
  author = {Yuan Zhao and Xuanhui Li and Jiacheng Cheng and Dongyu Hu and Huili Cao and X. Wang and Junhua He and Yikun Zhu and Jin Li},
  title = {{The impact of the COVID-19 pandemic on liver health: exploring shifts in social and psychosocial determinants of steatosis and fibrosis}},
  booktitle = {Frontiers in Medicine},
  year = {2026},
  doi = {10.3389/fmed.2026.1725338},
}
Figure